London, 25th February 2020: EMMAC Life Sciences Group, Europe’s leading independent cannabis company, is pleased to announce the launch of Medican, the UK’s first operational distance pharmacy dedicated to fulfilling medical cannabis prescriptions, a division of its wholly owned subsidiary, Rokshaw Limited (“Rokshaw”), a leading UK EU-GMP certified Specials manufacturer.
Medican has already processed more than 100 cannabis product prescriptions in the UK. As part of the EMMAC Life Sciences Group of companies, Medican is able to leverage a vertically integrated supply chain, intended to create value for predominantly self-funded private patients at this time.
Medican, as Rokshaw’s registered pharmacy, in conjunction with Rokshaw’s existing licenses, allows Rokshaw to import, manufacture and securely deliver medical cannabis products (”CBPM”) direct to UK-based patients.
Ed McDermott, Managing Director of EMMAC UK, commented: “We are very pleased to be announcing the launch of Medican as a service for patients in the UK. We believe our MHRA-approved medical cannabis manufacturing facility, combined with our experienced team of on-site pharmacists and health care professionals will provide an important service for the growing number of patients requiring medical cannabis.”
Rokshaw is EMMAC’s second GMP-certified laboratory and works in close conjunction with Medalchemy, the Company’s GMP-certified facility, which includes the research and development centre, in Spain. The full integration of the EMMAC supply chain (Good Agricultural and Collection Practice (“GACP”) cultivation; extraction and manufacturing in accordance with EU Good Manufacturing Practices (”GMP”); combined with licensed distribution channels for medical cannabis in the UK, Germany and Italy) positions EMMAC to deliver the highest-quality medical cannabis product for the UK and European market.
EMMAC Life Sciences Group is Europe’s leading independent cannabis company, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. With a unique supply and distribution network throughout Europe, EMMAC’s vision is to bring the life-enhancing potential of cannabis to the people who need it.
All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of EMMAC Life Sciences Ltd. There can be no assurance that such statements will prove to be accurate, achievable or recognisable in the near term.
Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. EMMAC Life Sciences Ltd assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.